Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDI Study of Mavorixafor with CYP3A Inducers in Healthy Participants
NCT06914869Phase 1Completed
- Sponsor
- X4 Pharmaceuticals, Inc.
- Start
- Feb 2025
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of mavorixafor in WHIM syndrome (WHIM) (2 arms), sponsored by X4 Pharmaceuticals, Inc. Primary endpoints: Maximum Observed Plasma Concentration at Day 18 and Area Under the Concentration-time Curve From Time Zero to the Last Quantifiable Concentration at Day 18. Started Feb 2025; status: completed.
02
Drugs
mavorixafor
03
Conditions
WHIM syndrome (WHIM)
Beyond the preview
Go deeper on NCT06914869.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06914869.